Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis
NCT01480076
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
901
Enrollment
INDUSTRY
Sponsor class
Conditions
Multiple Sclerosis
Interventions
DRUG:
Fampridine
Sponsor
Biogen